Latest news with #PRISMMarketView
Yahoo
28-05-2025
- Business
- Yahoo
PRISM MarketView Features SKYX Platforms Corp. Following Major Miami Project Win and Russell Index Inclusion
Company to Deploy Over 500,000 Smart Home Units in $3 Billion Development; Joins Russell 2000® and 3000® Indexes NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView, an investor-focused platform tracking small and emerging growth companies, today featured SKYX Platforms Corp. (NASDAQ: SKYX) following a series of significant milestones, including its selection as the exclusive smart home infrastructure provider for a $3 billion mixed-use development in Miami and its upcoming inclusion in the Russell 2000® and Russell 3000® Indexes. The 63-acre Miami project, located in the Little River District, will integrate SKYX's patented plug & play technologies across more than 5,700 residential units, including 2,400 affordable apartments. More than 500,000 SKYX smart home devices will be deployed as part of the project.'Our advanced plug & play smart platform was designed to support the next generation of urban developments,' said Rani Kohen, Founder, Inventor and Executive Chairman of SKYX Platforms Corp. 'We look forward to the opportunity to contribute to a connected, safer, and more efficient living environment.' In addition, SKYX announced its expected inclusion in the Russell 2000® and Russell 3000® Indexes as part of FTSE Russell's 2025 annual reconstitution. The company's addition will become effective after the market opens on June 27, 2025. SKYX recently reported record Q1 2025 results, including revenue of $20.1 million, 4.8% sequential gross margin improvement, and a 17% reduction in G&A expenses. The company expanded its footprint across the U.S. and Canada and reaffirmed its expectation to achieve cash flow positivity in the second half of 2025, supported by its razor-and-blade business model. Read the full feature on PRISM MarketView: For SKYX's Technologies Video Link CLICK HERE About SKYX Platforms electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 97 U.S. and global patents and patent pending applications. Additionally, the Company owns over 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at or follow us on LinkedIn. About PRISM MarketView PRISM MarketView is a financial media platform focused on highlighting emerging growth companies and breakthrough innovation across public markets. Through original editorial, video features, and executive Q&A content, PRISM delivers timely insights and elevates visibility for high-potential companies. PRISM also maintains a suite of proprietary indexes tracking momentum across sectors including biotech, AI, and consumer tech. Learn more at PRISM MarketView does not provide investment advice. Disclaimer This communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its clients' securities. See Contact:PRISM MarketView info@ 646-863-6341 A photo accompanying this announcement is available at
Yahoo
22-05-2025
- Business
- Yahoo
PRISM MarketView Launches Emerging Sports Index
Emerging sports companies are reshaping the industry through innovation in team ownership, media, data analytics, and the expanding legal sports betting market NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today announces the launch of its PRISM Emerging Sports Index in response to significant global growth and transformation in the sports industry. The new PRISM index tracks emerging companies elevating the industry through professional sports teams, sports media platforms, athletics data or analytics solutions, and legal sports betting or fantasy sports services. Analysts project that by 2028 the global sports market could reach over $680 billion and is expected to grow at a compound annual growth rate of 9.13% between 2022 and global sports industry is undergoing a transformation driven by digital engagement, data analytics, and the rapid growth of legal sports betting. From traditional team ownership and franchise operations to cutting-edge betting platforms and fan engagement technologies, the business of sports is becoming more dynamic. PRISM MarketView reviewed a selection of the companies set to transform the sports landscape for the next several years. Motorsport Games Inc. Motorsport Games (Nasdaq: MSGM) blends cutting-edge racing video games with dynamic esports competitions and content, delivering immersive experiences for racing enthusiasts and gamers worldwide. Most recently the company reported its first quarter financials posting net income of $1.0 million for Q1 2025, a significant improvement from a $1.7 million loss in Q1 2024, driven by reduced operating expenses and gains from settlements. The company raised $2.5 million in a private placement led by VR company Pimax and saw momentum from its Le Mans Ultimate title, with a major update planned for June. Despite improved financials and increased cash reserves, Motorsport Games continues to explore strategic options and cost-cutting initiatives to address ongoing liquidity challenges. SharpLink Gaming Inc. SharpLink Gaming, Inc. (Nasdaq: SBET) is an online performance marketing company specializing in the sports betting and iGaming industries. The company connects sports fans with licensed sportsbook and casino operators through targeted affiliate marketing strategies, utilizing state-specific web domains and advanced analytics to drive user engagement and conversions. Most recently, SharpLink priced a public offering of up to 1,530,612 shares of common stock at $2.94 per share, expecting to raise approximately $4.5 million in gross proceeds. The proceeds are intended for working capital, general corporate purposes, and other uses outlined in the filed prospectus. Sportsman's Warehouse Holdings, Inc. Sportsman's Warehouse Holdings (Nasdaq: SPWH) is a leading U.S.-based outdoor sporting goods retailer specializing in gear and apparel for hunting, fishing, camping, shooting, and other outdoor activities and sports. Founded in 1986 the company operates over 140 stores across more than 30 states, complemented by a robust e-commerce platform. Most recently the company announced Susan Sanderson as its Chief Marketing Officer, recognizing her pivotal role in driving recent business improvements since joining in July 2024. With over 20 years of experience in omni-channel retail and turnarounds, Sanderson is expected to lead the company's next phase of growth by sharpening brand strategy and enhancing customer engagement. CEO Paul Stone praised her transformative leadership and speed in elevating marketing and e-commerce operations, which have already contributed to the company's momentum. About PRISM MarketView:Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at and follow us on X. PRISM MarketView does not provide investment advice. Contact:PRISM MarketViewinfo@ A photo accompanying this announcement is available at in to access your portfolio
Yahoo
12-05-2025
- Health
- Yahoo
PRISM MarketView Honors Mental Health Awareness Month with a Spotlight on Emerging Innovators
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- In recognition of Mental Health Awareness Month, PRISM MarketView reaffirms its commitment to highlighting the critical importance of mental health and the ongoing efforts to improve mental well-being across the nation. Established in 1949 by Mental Health America, Mental Health Awareness Month serves to educate the public about mental illnesses, promote mental wellness, and reduce the stigma associated with mental health conditions. This year's theme, "Turn Awareness into Action," encourages individuals and organizations to move beyond awareness and take tangible steps toward mental health advocacy and support. Despite increased awareness, over 30 million people in the U.S. still lack access to comprehensive, high-quality mental health care. This disparity underscores the urgent need for continued efforts to expand mental health services and resources. Psychedelics, such as psilocybin and MDMA, are showing promising results in treating mental health conditions like depression, PTSD, and anxiety. Clinical trials have demonstrated that, under controlled settings, these substances can help "reset" neural pathways, allowing patients to process trauma and break out of negative thought patterns. As research expands, psychedelics are emerging as powerful tools in modern psychiatry, offering new hope for individuals who haven't responded to conventional treatments. At PRISM MarketView, we recognize the pivotal role that innovation and investment play in advancing mental health care. Our PRISM Emerging Mental Health Index and PRISM Emerging Psychedelics Index tracks the performance of small-cap companies at the forefront of developing novel therapies, digital health solutions, and supportive technologies aimed at improving mental health honor of Mental Health Awareness Month, PRISM MarketView is excited to spotlight four pioneering companies within our emerging indices: Sage Therapeutics Sage Therapeutics, Inc. is a biopharmaceutical company, dedicated to pioneering solutions that deliver life-changing brain health medicines. The company focuses on developing treatments for central nervous system (CNS) disorders, with a particular emphasis on depression, neurology, and neuropsychiatry. Postpartum depression (PPD) affects over 3 million in the US and are at greater risk of developing major depression later on in life. If left untreated, postpartum depression can severely impair a parent's ability to care for their child and themselves, leading to diminished energy, difficulty concentrating on the baby's needs, mood instability, and, in extreme cases, an increased risk of suicide. Sage has developed two FDA-approved treatments for PPD: ZULRESSO® (brexanolone), an intravenous therapy, and ZURZUVAE® (zuranolone), the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. Beyond PPD, Sage is advancing a robust pipeline targeting unmet needs in brain health, including SAGE-324 for essential tremor and SAGE-718 for cognitive disorders associated with diseases such as Huntington's and Parkinson's. The company has strategic collaborations with Biogen and Shionogi & Co., Ltd. to develop and commercialize its products in various global markets. Talkspace, Inc. Talkspace, Inc. is a leading virtual behavioral healthcare company. Founded in 2012, Talkspace pioneered message-based therapy, offering individuals, couples, and teens convenient access to licensed therapists through text, audio, and video communications. The platform also provides psychiatry services, including medication management for adults. With a network of over 5,000 licensed clinicians, Talkspace addresses more than 150 mental health conditions and treatment modalities. The company's services are accessible via a fully encrypted web and mobile platform that complies with HIPAA and other regulatory standards. Talkspace partners with major health plans and employers, covering over 130 million lives across the United States. Mind Medicine Inc. Mind Medicine (MindMed) is a late-stage clinical biopharmaceutical company dedicated to developing innovative treatments for brain health disorders, including generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD). The company is advancing a pipeline of novel product candidates, with a focus on psychedelic-inspired therapies. MindMed's lead candidate, MM120 ODT (lysergide D-tartrate), is a pharmaceutically optimized form of LSD. The company is conducting three pivotal Phase 3 trials: Voyage and Panorama for GAD and Emerge for MDD. These studies are actively enrolling participants, with topline data expected in 2026. In March 2024, the FDA granted MM120 Breakthrough Therapy Designation for GAD, recognizing its potential to address significant unmet medical needs. Another key program is MM402 (R(-)-MDMA), a non-hallucinogenic enantiomer of MDMA, being developed for ASD. MindMed completed a Phase 1 single-ascending dose study in healthy volunteers to assess its safety, pharmacokinetics, and pharmacodynamics. The company plans to initiate further studies to evaluate MM402's efficacy in treating ASD. Financially, MindMed reported cash, cash equivalents, and investments totaling $245.5 million as of March 31, 2025, providing a runway to fund operations into 2027. The company also amended its loan agreement with K2 HealthVentures, securing up to $120 million based on milestone achievements and extending the interest-only period through at least May 1, 2027. Cybin Inc. Cybin Inc. is a clinical-stage biopharmaceutical company headquartered in Toronto, Canada, with operations in the United States, the United Kingdom, the Netherlands, and Ireland. Founded in 2019, Cybin is dedicated to developing psychedelic-based therapeutics aimed at addressing unmet needs in mental health care. The company's lead candidate, CYB003, is a proprietary deuterated psilocybin analog currently in Phase 3 clinical trials for the treatment of major depressive disorder (MDD). CYB004, a deuterated dimethyltryptamine (DMT) molecule, is in Phase 2 development targeting generalized anxiety disorder (GAD). Cybin's pipeline also includes CYB005, a phenethylamine derivative in preclinical stages for neuroinflammation. The company has an extensive intellectual property portfolio, with over 70 granted patents and more than 220 pending applications. About PRISM MarketView: Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, next-gen tech & AI, consumer products and beyond. Visit us at and follow us on Twitter. PRISM MarketView does not provide investment advice. Contact:PRISM MarketViewinfo@ 646-863-6341 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12-05-2025
- Health
- Yahoo
PRISM MarketView Honors Mental Health Awareness Month with a Spotlight on Emerging Innovators
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- In recognition of Mental Health Awareness Month, PRISM MarketView reaffirms its commitment to highlighting the critical importance of mental health and the ongoing efforts to improve mental well-being across the nation. Established in 1949 by Mental Health America, Mental Health Awareness Month serves to educate the public about mental illnesses, promote mental wellness, and reduce the stigma associated with mental health conditions. This year's theme, "Turn Awareness into Action," encourages individuals and organizations to move beyond awareness and take tangible steps toward mental health advocacy and support. Despite increased awareness, over 30 million people in the U.S. still lack access to comprehensive, high-quality mental health care. This disparity underscores the urgent need for continued efforts to expand mental health services and resources. Psychedelics, such as psilocybin and MDMA, are showing promising results in treating mental health conditions like depression, PTSD, and anxiety. Clinical trials have demonstrated that, under controlled settings, these substances can help "reset" neural pathways, allowing patients to process trauma and break out of negative thought patterns. As research expands, psychedelics are emerging as powerful tools in modern psychiatry, offering new hope for individuals who haven't responded to conventional treatments. At PRISM MarketView, we recognize the pivotal role that innovation and investment play in advancing mental health care. Our PRISM Emerging Mental Health Index and PRISM Emerging Psychedelics Index tracks the performance of small-cap companies at the forefront of developing novel therapies, digital health solutions, and supportive technologies aimed at improving mental health honor of Mental Health Awareness Month, PRISM MarketView is excited to spotlight four pioneering companies within our emerging indices: Sage Therapeutics Sage Therapeutics, Inc. is a biopharmaceutical company, dedicated to pioneering solutions that deliver life-changing brain health medicines. The company focuses on developing treatments for central nervous system (CNS) disorders, with a particular emphasis on depression, neurology, and neuropsychiatry. Postpartum depression (PPD) affects over 3 million in the US and are at greater risk of developing major depression later on in life. If left untreated, postpartum depression can severely impair a parent's ability to care for their child and themselves, leading to diminished energy, difficulty concentrating on the baby's needs, mood instability, and, in extreme cases, an increased risk of suicide. Sage has developed two FDA-approved treatments for PPD: ZULRESSO® (brexanolone), an intravenous therapy, and ZURZUVAE® (zuranolone), the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. Beyond PPD, Sage is advancing a robust pipeline targeting unmet needs in brain health, including SAGE-324 for essential tremor and SAGE-718 for cognitive disorders associated with diseases such as Huntington's and Parkinson's. The company has strategic collaborations with Biogen and Shionogi & Co., Ltd. to develop and commercialize its products in various global markets. Talkspace, Inc. Talkspace, Inc. is a leading virtual behavioral healthcare company. Founded in 2012, Talkspace pioneered message-based therapy, offering individuals, couples, and teens convenient access to licensed therapists through text, audio, and video communications. The platform also provides psychiatry services, including medication management for adults. With a network of over 5,000 licensed clinicians, Talkspace addresses more than 150 mental health conditions and treatment modalities. The company's services are accessible via a fully encrypted web and mobile platform that complies with HIPAA and other regulatory standards. Talkspace partners with major health plans and employers, covering over 130 million lives across the United States. Mind Medicine Inc. Mind Medicine (MindMed) is a late-stage clinical biopharmaceutical company dedicated to developing innovative treatments for brain health disorders, including generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD). The company is advancing a pipeline of novel product candidates, with a focus on psychedelic-inspired therapies. MindMed's lead candidate, MM120 ODT (lysergide D-tartrate), is a pharmaceutically optimized form of LSD. The company is conducting three pivotal Phase 3 trials: Voyage and Panorama for GAD and Emerge for MDD. These studies are actively enrolling participants, with topline data expected in 2026. In March 2024, the FDA granted MM120 Breakthrough Therapy Designation for GAD, recognizing its potential to address significant unmet medical needs. Another key program is MM402 (R(-)-MDMA), a non-hallucinogenic enantiomer of MDMA, being developed for ASD. MindMed completed a Phase 1 single-ascending dose study in healthy volunteers to assess its safety, pharmacokinetics, and pharmacodynamics. The company plans to initiate further studies to evaluate MM402's efficacy in treating ASD. Financially, MindMed reported cash, cash equivalents, and investments totaling $245.5 million as of March 31, 2025, providing a runway to fund operations into 2027. The company also amended its loan agreement with K2 HealthVentures, securing up to $120 million based on milestone achievements and extending the interest-only period through at least May 1, 2027. Cybin Inc. Cybin Inc. is a clinical-stage biopharmaceutical company headquartered in Toronto, Canada, with operations in the United States, the United Kingdom, the Netherlands, and Ireland. Founded in 2019, Cybin is dedicated to developing psychedelic-based therapeutics aimed at addressing unmet needs in mental health care. The company's lead candidate, CYB003, is a proprietary deuterated psilocybin analog currently in Phase 3 clinical trials for the treatment of major depressive disorder (MDD). CYB004, a deuterated dimethyltryptamine (DMT) molecule, is in Phase 2 development targeting generalized anxiety disorder (GAD). Cybin's pipeline also includes CYB005, a phenethylamine derivative in preclinical stages for neuroinflammation. The company has an extensive intellectual property portfolio, with over 70 granted patents and more than 220 pending applications. About PRISM MarketView: Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, next-gen tech & AI, consumer products and beyond. Visit us at and follow us on Twitter. PRISM MarketView does not provide investment advice. Contact:PRISM MarketViewinfo@ 646-863-6341 A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-04-2025
- Business
- Yahoo
PRISM MarketView Spotlights Opus Genetics in New Q&A with CEO George Magrath
Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic Programs NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr. George Magrath, Chief Executive Officer of Opus Genetics, Inc. ('Opus Genetics' or the 'Company') (Nasdaq: IRD), a clinical-stage gene therapy company developing treatments for inherited retinal diseases (IRDs) and broader ophthalmic George Magrath, Chief Executive Officer of Opus Genetics, Inc. In the interview, Dr. Magrath outlines Opus Genetics' recent milestones, including: Completion of enrollment in two Phase 3 clinical trials: VEGA-3 for presbyopia and LYNX-2 for post-LASIK night vision disturbances; FDA Fast Track designation for phentolamine ophthalmic solution to treat chronic night driving impairment; and Upcoming data presentations for OPGx-LCA5, an AAV-based gene therapy targeting Leber congenital amaurosis 5. The feature also explores Opus Genetics' strategy to seek to build a repeatable gene therapy platform and anticipated clinical milestones throughout 2025.'With multiple regulatory milestones and clinical readouts, as well as an expanding pipeline, 2025 has the potential to be a pivotal year for Opus Genetics,' said Dr. Magrath. The full Q&A, published by PRISM MarketView, is available here: Opus GeneticsOpus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with IRDs and other treatments for ophthalmic disorders. Our pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Our most advanced investigational gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and is currently being evaluated in a Phase 1/2 open-label, dose-escalation trial, with encouraging early data. Our pipeline also includes BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy. Phentolamine Ophthalmic Solution 0.75% is currently being evaluated in Phase 3 trials for presbyopia and dim (mesopic) light vision disturbances. We have reached agreement with the FDA under SPA for a Phase 3 trial to evaluate oral APX3330 for the treatment of DR more information, please visit Forward-Looking Statements This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning data from and future enrollment for the Company's clinical trials, the results of the Company's ongoing Phase 1/2 trial with respect to OPGx LCA5, and the Company's pipeline of additional indications. These forward-looking statements relate to the Company, its business prospects and its results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause its actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under Part II, Item 1A, 'Risk Factors', in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in the Company's other filings with the U.S. Securities and Exchange Commission (the 'SEC'). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this article. In some cases, you can identify forward-looking statements by the following words: 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'aim,' 'may,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The Company undertakes no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise, except as may be required by applicable law. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: Failure to successfully integrate our businesses with former Opus Genetics Inc. could have a material adverse effect on our business, financial condition and results of operations; The acquisition of former Opus Genetics Inc. significantly expanded our product pipeline and business operations and shifted our business strategies, which may not improve the value of our common stock; Our gene therapy product candidates are based on a novel technology that is difficult to develop and manufacture, which may result in delays and difficulties in obtaining regulatory approval; Our planned clinical trials may face substantial delays, result in failure, or provide inconclusive or adverse results that may not satisfy FDA requirements to further develop our therapeutic products; Changes in regulatory requirements could result in increased costs or delays in development timelines; We depend heavily on the success of our product pipeline; if we fail to find strategic partners or fail to adequately develop or commercialize our pipeline products, our business will be materially harmed; Others may discover, develop, or commercialize products similar to those in our pipeline before or more successfully than we do or develop generic variants of our products even while our product patents remain active, thereby reducing our market share and potential revenue from product sales; We do not currently have any sales or marketing infrastructure in place and we have limited drug research and discovery capabilities; The future commercial success of our products could significantly depend upon several uncertain factors, including third-party reimbursement practices and the existence of competitors with similar products; Product liability lawsuits against us or our suppliers or manufacturers could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop; Failure to comply with health and safety laws and regulations could lead to material fines ; We have not generated significant revenue from sales of any products and expect to incur losses for the foreseeable future; Our future viability is difficult to assess due to our short operating history and our future need for substantial additional capital, which could be limited by any adverse developments that affect the financial services industry; Raising additional capital may cause our stockholders to be diluted, among other adverse effects; We operate in a highly regulated industry and face many challenges complying to sudden changes in legislative reform or the regulatory environment, which affects our pipeline stability and could impair our ability to compete in international markets; We may not receive regulatory approval to market our developed product candidates within or outside of the U.S.; With respect to any of our product candidates that receive marketing approval, we may be subject to substantial penalties if we fail to comply with applicable regulatory requirements; Our potential relationships with healthcare providers and third-party payors will be subject to certain healthcare laws and regulations, which could expose us to extensive potential liabilities; We rely on third parties for material aspects of our business, such as conducting our nonclinical and clinical trials and supplying and manufacturing bulk drug substances, which exposes us to certain risks; We may be unsuccessful in entering into or maintaining licensing arrangements (such as the Viatris License Agreement) or establishing strategic alliances on favorable terms, which could harm our business; Our current focus on the cash-pay utilization for future sales of RYZUMVI may limit our ability to increase sales or achieve profitability with this product; Inadequate patent protection for our product candidates may result in our competitors developing similar or identical products or technology, which would adversely affect our ability to successfully commercialize; We may be unable to obtain full protection for our intellectual property rights under U.S. or foreign laws; We may become involved in lawsuits for a variety of reasons associated with our intellectual property rights, including alleged infringement suits initiated by third parties; We are dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy; As we grow, we may not be able to operate internationally or adequately develop and expand our sales, marketing, distribution, and other corporate functions, which could disrupt our operations; The market price of our common stock is expected to be volatile and subject to certain dilutive risks associated with our Equity Line of Credit arrangement; and Factors out of our control related to our securities, such as securities litigation or actions of activist stockholders, could adversely affect our business and stock price and cause us to incur significant expenses. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive. Readers are urged to carefully review and consider the various disclosures made by the Company in this statement and in the Company's other reports filed with the SEC that advise interested parties of the risks and factors that may affect the Company's business. All forward-looking statements contained in this article speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by applicable law. About PRISM MarketViewPRISM MarketView is a financial media platform focused on highlighting emerging growth companies and breakthrough innovation across public markets. Through original editorial, video features, and executive Q&A content, PRISM delivers timely insights and elevates visibility for high-potential companies. PRISM also maintains a suite of proprietary indexes tracking momentum across sectors including biotech, AI, and consumer tech. Learn more at PRISM MarketView does not provide investment advice. DisclaimerThis communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (together "PCG"). PCG is not a registered or licensed broker-dealer nor investment adviser. No information contained in this communication constitutes an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. PCG may be compensated by respective clients for publicizing information relating to its clients' securities. See Contact:PRISM MarketViewinfo@ Photos accompanying this announcement are available at:
